Galapagos NV - GLPGF stock
OTC Symbol: GLPGF | OTC Tier: Pink Current
Galapagos NV is an integrated biopharmaceutical company based in Mechelen, Belgium, that focuses on the discovery, development, and commercialization of various medicines to address high unmet medical needs; its pipeline includes filgotinib, a JAK1 inhibitor in clinical trials for rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis, as well as other pipeline products such as GLPG3667, GLPG5101, and GLPG5201 in various phases of clinical development for different indications; the company also has collaboration agreements with Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG.
Galapagos NV has its origin in Belgium and was founded in 1999. The company was established as a biotechnology firm with a focus on drug discovery, development, and commercialization to address high unmet medical needs. The company's name "Galapagos" was inspired by the Galápagos Islands, an archipelago in the Pacific Ocean known for its unique biodiversity. The name reflects the company's commitment to exploring and discovering novel therapies and treatments to tackle challenging medical conditions.
Galapagos NV started its journey as a biopharmaceutical research organization, specializing in target identification, drug screening, and early-stage drug development. The company's primary goal was to leverage its expertise in drug discovery to identify promising candidates for further development and clinical trials. Over the years, Galapagos NV expanded its activities and pipeline, advancing potential drug candidates in various therapeutic areas, including inflammatory and autoimmune diseases, fibrosis, and oncology.
One of the company's key developments was the discovery and development of filgotinib, a JAK1 inhibitor. Filgotinib became a significant focus of Galapagos NV's research and clinical efforts, targeting multiple autoimmune and inflammatory conditions.
Galapagos NV's progress and potential in drug development caught the attention of several major pharmaceutical companies. To strengthen its position and expand its reach, the company entered into strategic collaboration agreements with global biopharmaceutical firms such as Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. These collaborations provided Galapagos NV with additional resources, expertise, and support to advance its drug candidates through later-stage clinical trials and commercialization.